Innovative stem cell technologies have potential to treat  Alzheimer’s disease.

http://runrabbitrunsteamboat.com/welcome/viagra-sample-25mg/1/ ppt on essay writing dissertation data analysis paying people to do assignments go site go here cialis and women go site viagra for sale sheffield viagra juice go site female viagra sprout pharmaceuticals watch les effets nГ©gatifs de viagra baby thesis outline generic cialis online go to site do my essay literature essays order enhance herbal viagra writing paper with lines order argumentative essay cheap and quick viagra pumpkin writing paper graduate nurse resume help https://www.xpcc.com/canadian-history-homework-help/ greencanadacare critical thinking and writing Today, there is no cure for Alzheimer’s disease and dementia. In 2015, dementia affected more than 46.8 million people worldwide, according to Alzheimer’s Disease International, and an estimated 60-80 percent of those patients have Alzheimer’s disease. The number of dementia cases is expected to grow to 74.7 million in 2030 and to reach 131.5 million in 2050. Stemedica International is the only company to leverage three patented, stem cell technologies (itMSCs, itNSCs and related growth factors) for therapies that may be able to address the global, unmet need for treatments of degenerative conditions, including Alzheimer’s disease and vascular dementia. Stemedica International is also exploring opportunities to prevent the condition, based on promising pre-clinical data.

Stemedica International is using cGMP allogeneic stem cells derived from healthy adult volunteers in clinical trials. Manufactured in a licensed facility under cGMP conditions, the company has successfully completed the safety phase of a clinical trial.